FDA lifts partial clinical hold on Zentalis' azenosertib studies; enrollment to resume

Zentalis Pharmaceuticals, Inc.

FDA cleared resumption of enrollment in all ongoing azenosertib studies with no changes to the clinical development plan.
Partial clinical hold was placed June 18, 2024; lifted after FDA review of comprehensive safety assessment.
Zentalis on track to present azenosertib monotherapy data and additional updates in Q4 2024.
CEO cites unwavering confidence in azenosertib's therapeutic index for gynecologic malignancies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.